t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.

Abstract

A 42-year-old male patient with a history of occupational exposure to benzene presented with pancytopenia. His bone marrow showed evidence of trilineage dysplasia and cytogenetic analysis revealed a unique t(9;13)(q34;q12) translocation. Five months after diagnosis he developed secondary AML. He was treated with four courses of chemotherapy and an autologous bone marrow transplantation (BMT). Four years post-transplantation he remains in haematological and morphological remission though the cytogenetic abnormality is still present in all metaphases examined.

• Authors: P Mahendra, E M Richards, P Sinclair, E Nacheva, R E Marcus
• Journal: Clinical and laboratory haematology (Clin Lab Haematol) Vol. 18 Issue 2 Pg. 121-2 (Jun 1996) ISSN: 0141-9854 [Print] England
• PMID: 8866147 (Publication Type: Case Reports, Journal Article)

Chemical References

• Solvents
• Etoposide
• Benzene
• Melphalan
• Carmustine

Topics

• Acute Disease
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Benzene (adverse effects)
• Bone Marrow (pathology)
• Bone Marrow Transplantation
• Carmustine (administration & dosage)
• Chromosomes, Human, Pair 13 (ultrastructure)
• Chromosomes, Human, Pair 9 (ultrastructure)
• Combined Modality Therapy
• Etoposide (administration & dosage)
• Follow-Up Studies
• Humans
• Leukemia, Myeloid (chemically induced, drug therapy, genetics, pathology, therapy)
• Male
• Melphalan (administration & dosage)
• Myelodysplastic Syndromes (chemically induced, complications, genetics, pathology)
• Neoplastic Stem Cells (pathology)
• Occupational Diseases (chemically induced, complications)
• Occupational Exposure
• Pancytopenia (etiology)
• Remission Induction
• Solvents (adverse effects)
• Translocation, Genetic
• Transplantation, Homologous